A new study assessed patients with non–small cell lung cancer (NSCLC) through a database of 28,998 patients with cancer, approximately 85% of whom were treated with traditional oncology means (chemotherapy, radiation, surgery).  It generated very interesting data by linking electronic health record–derived longitudinal clinical data with comprehensive tumor genomic profiling. Analysis of 4064 patients with NSCLC revealed clinical, genomic, and therapeutic associations that yielded novel, clinically meaningful insights.

Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female):

  • 3183 (78.3%) had a history of smoking,
  • 3153 (77.6%) had nonsquamous cancer, and
  • 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0%] with ROS1 alterations).

The EGFR gene (Epidermal growth factor receptor) is a trans-membrane glycoprotein, meaning it encodes (creates) a protein that, in this case, regulates signaling pathways to control cellular proliferation. Defects in the EGFR gene are believe to contribute to increased cancer growth.(1)

ALK (anaplastic lymphoma kinase) is a gene that tells your body how to make proteins that help cells talk to each other. If you have lung cancer with an ALK rearrangement, part of this gene is broken and attached to another gene. An “ALK positive” lung cancer is thought to be more aggressive.

ROS1 positive lung cancer is a lung tumor which tests positive for a ROS1 gene rearrangement, one of the known “driver mutations” found in lung cancer. ROS1 is a receptor tyrosine kinase that has recently been shown to undergo genetic rearrangements in a variety of human cancers, including glioblastoma, non–small cell lung cancer (NSCLC), cholangiocarcinoma, ovarian cancer, gastric adenocarcinoma, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, and epithelioid hemangioendothelioma.

What could someone Do?

One of the most important of these natural compounds in assisting patients with gene defects is curcumin. Curcumin is found in turmeric, a yellow-colored spice of the perennial herb Curcuma longa, which has been used widely for centuries not only in cooking but in traditional therapies for various diseases, especially as an anti-inflammatory agent. Curcumin and its metabolite, tetrahydrocurcumin have been extensively investigated as anti-inflammatory and anti-cancer molecules. The wide variety of medicinal effects of curcumin is a result of its ability to interact with a diverse range of molecular targets.

A desirable anticancer drug must be selective for and cytotoxic to cancer cells, have minimal side effects, and be cost-effective. Since 1952, 89 drugs have been approved by the FDA for the treatment of various cancer types. Agents that selectively target cancer-specific gene mutations are effective because they can discriminate between normal and malignant forms. However, most targets are not cancer specific; for example, CD20 is a normal B-cell differentiation protein, and epidermal growth factor receptor (EGFR) is also expressed on normal cells. (2) See the known, researched effects of curcumin on cancer proliferative pathways in the chart below:

curcumin for cancer


These are all known metabolic pathways that have been shown to promote cancer. Curcumin blocks all these!

Consider adding CurcuClear, 1-4/day to your protocol!

(1) Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update Gillian Bethune,1 Drew Bethune,2 Neale Ridgway,3 and Zhaolin Xu1

(2) Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004;3:1035–1042.


NOTE: All of the above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.